

VNSG 1227

Medication Administration

Ch. 10 Reading Medication Labels

Learning Objectives for Chapter 10

- Identify the trade and generic names of medications.
- Describe the form in which medication is supplied.
- Distinguish the total volume of medication container from the dosage strength.
- Apply directions for mixing or preparing a medication where necessary.
- Identify information on combined medication labels.



1. Right Patient
2. Right Medication
3. Right Dosage
4. Right Route
5. Right Time
6. Right Documentation
7. Right Client Education
8. Right to Refuse
9. Right Assessment
10. Right Evaluation

Medication Administration

Reading Medication Labels

- To administer medication safely to patients, the nurse needs to **accurately read and interpret the information on a medication label**
- Label indicates information to perform dosage calculation

A

NDC 10019-178-44

Morphine Sulfate Injection, USP 

10 mg/mL **Rx only**

**FOR SC, IM OR SLOW IV USE
NOT FOR EPIDURAL OR
INTRATHECAL USE**

25 x 1 mL DOSETTE® Vials

Baxter **ESILEDERLE™**
Mfd. for an affiliate of Baxter Healthcare Corporation
Deerfield, IL 60015 USA
by: Elkins-Sinn, Cherry Hill, NJ 08003 400-830-01

Each mL contains morphine sulfate 10 mg, monobasic sodium phosphate, monohydrate 10 mg, dibasic sodium phosphate, anhydrous 2.8 mg, sodium formaldehyde sulfoxylate 3 mg and phenol 2.5 mg in Water for Injection, pH 2.5-6.5; sulfuric acid added, if needed, for pH adjustment. Sealed under nitrogen.

Usual Dosage: See package insert.

PROTECT FROM LIGHT.

Store at 15°-30°C (59°-86°F). Avoid freezing.

NOTE: Do not use if color is darker than pale yellow, if it is discolored in any other way or if it contains a precipitate.

DOSETTE® is a registered trademark of A.H. Robins Company.

10019 17844

B

N 06416 00610 1

NDC 0641-6006-10 **Rx only**

Atropine Sulfate Injection, USP

8 mg/20 mL (0.4 mg/mL)

FOR IM, IV OR SC USE

10 x 20 mL Multiple Dose Vials

Each mL contains: Atropine Sulfate 0.4 mg; Benzyl Alcohol 9 mg; Sodium Chloride 9 mg; Water for Injection qs; pH is adjusted with Sulfuric Acid if necessary, pH 3.0-6.5.

Usual Dosage: See package insert.

Store at 20°-25°C (68°-77°F) (See USP Controlled Room Temperature).

Manufactured by:
WEST-WARD
Easton, NJ 07724 USA
462-422-01

LOT: EXPI:

Pertinent information

- Medication name (generic or brand)
- Form
- Total volume
- Total amount in container (for solid forms)
- Route of administration
- Warnings
- Storage requirements
- Manufacturing information
- Expiration date
- National drug code

Classification of Drugs

- ❑ 3 classifications
 - ❑ Over the counter drugs (OTC)
 - Ibuprofen, Tylenol, Aleve
 - ❑ Prescription drugs (Rx)
 - Naprosyn, Amoxicillin
 - ❑ Controlled Substances or scheduled drugs
 - Both OTC and RX medicines fall under a schedule of drug
-

Drug Schedules

- **Goal:** to organize the control of drugs under **5** classifications (schedules of controlled substances)
- Potential for abuse
- Accepted medical use
- **Schedule I:** High potential for abuse; no accepted medical use (LSD)
- **Schedule II:** High potential for abuse; Some accepted medical use (cocaine)
- **Schedule III:** Some potential for abuse; accepted medical use (mixtures-1.8%codeine)
- **Schedule IV:** Low potential for abuse; accepted medical use (valium)
- **Schedule V:** Minimal abuse potential; widespread medical use (laxatives)

Confusing non standard labels

A

NDC 10019-178-44

Morphine ©
Sulfate Injection, USP

10 mg/mL
FOR SC, IM OR SLOW IV USE
NOT FOR EPIDURAL OR
INTRATHECAL USE
25 x 1 mL DOSETTE® Vials

Baxter **ESILEDERLE™**
Mfd. for an affiliate of **Baxter Healthcare Corporation**
Deerfield, IL 60015 USA
by: Elkins-Sinn, Cherry Hill, NJ 08003 400-830-01

Each mL contains morphine sulfate 10 mg, monobasic sodium phosphate, monohydrate 10 mg, dibasic sodium phosphate, anhydrous 2.8 mg, sodium formaldehyde sulfoxylate 3 mg and phenol 2.5 mg in Water for Injection. pH 2.5-6.5; sulfuric acid added, if needed, for pH adjustment. Sealed under nitrogen.
Usual Dosage: See package insert.
PROTECT FROM LIGHT.
Store at 15°-30°C (59°-86°F). Avoid freezing.
NOTE: Do not use if color is darker than pale yellow, if it is discolored in any other way or if it contains a precipitate.
DOSETTE® is a registered trademark of A.H. Robins Company.

10019 17844

B

NDC 0641-6006-10 **Rx only**

Atropine
Sulfate Injection, USP

8 mg/20 mL (0.4 mg/mL)
FOR IM, IV OR SC USE
10 x 20 mL Multiple Dose Vials

Each mL contains: Atropine Sulfate 0.4 mg; Benzyl Alcohol 9 mg; Sodium Chloride 9 mg; Water for Injection qs; pH is adjusted with Sulfuric Acid if necessary. pH 3.0-6.5.
Usual Dosage: See package insert.
Store at 20°-25°C (68°-77°F) (See USP Controlled Room Temperature).

Manufactured by:
WEST-WARD
Easttown, NJ 07724 USA
452-422-01

LOT: _____
EXP: _____

Class II ???

Controlled Substance Act

Schedule I -
(MOST DANGEROUS)
Controlled substances that have no established medical usage, cannot be used safely, and have great potential for abuse. This schedule includes:

- heroin
- LSD
- mescaline
- peyote
- methaqualone
- psilocybin
- marijuana
- hashish
- other specified hallucinogens

Reading medication labels

- **Generic name**-is the official name of the medication
- Every medication has **one** official name and by law must be identified in the medication label.
- Generic names are given by the first manufacturer developers
- Most prescribers usually order medication by the generic name
- Pharmacist dispense medication by generic name to decrease cost
- **Important for Nurses to know both the brand and generic name of the medication.**
- **Always crosscheck medications** to prevent inaccurate medication ID, failure to crosscheck is a violation of the rights of medication administration.



Common medications may have only generic names

Generic name



NOTE: PRICES FROM CVS.COM; PHOTO: MIRA ZAKI/CNNMONEY

Brand-Name vs Generic Drugs



No Difference	Active Ingredient	No Difference
Higher in Cost	Price	Lower in Cost
Covered if no Generic Form Exists	Insurance Coverage	Normally Always Covered
Tested and Approved by the FDA	Inactive Ingredients	May Differ - But Proven to be Acceptable by the FDA
No Difference	Strength/Dosage	No Difference
Drugs are Standard in Size, Color, Packaging, etc.	Appearance/Look	Packaging and the Drug Itself may Look Different

Generic names vs Trade names

- sildenafil
- furosemide
- isotretinoin
- acetaminophen
- sertraline
- bupropion
- zolpidem
- fluoxetine

Generic names vs Trade names

- sildenafil Viagra
- furosemide
- isotretinoin
- acetaminophen
- Sertraline
- Bupropion
- zolpidem
- fluoxetine

Generic names vs Trade names

- sildenafil Viagra
- furosemide Lasix
- isotretinoin
- acetaminophen
- Sertraline
- Bupropion
- zolpidem
- fluoxetine

Generic names vs Trade names

- sildenafil Viagra
- furosemide Lasix
- isotretinoin Accutane
- acetaminophen
- Sertraline
- Bupropion
- zolpidem
- fluoxetine

Generic names vs Trade names

- sildenafil Viagra
- furosemide Lasix
- isotretinoin Accutane
- acetaminophen Tylenol
- Sertraline
- Bupropion
- zolpidem
- fluoxetine

Generic names vs Trade names

- sildenafil Viagra
- furosemide Lasix
- isotretinoin Accutane
- acetaminophen Tylenol
- Sertraline Zoloft
- Bupropion
- zolpidem
- fluoxetine

Generic names vs Trade names

- sildenafil Viagra
- furosemide Lasix
- isotretinoin Accutane
- acetaminophen Tylenol
- Sertraline Zoloft
- Bupropion Wellbutrin
- zolpidem
- fluoxetine

Generic names vs Trade names

- sildenafil Viagra
- furosemide Lasix
- isotretinoin Accutane
- acetaminophen Tylenol
- Sertraline Zoloft
- Bupropion Wellbutrin
- zolpidem Ambien
- fluoxetine

Generic names vs Trade names

- sildenafil Viagra
- furosemide Lasix
- isotretinoin Accutane
- acetaminophen Tylenol
- Sertraline Zoloft
- Bupropion Wellbutrin
- zolpidem Ambien
- fluoxetine Prozac

NDC 10019-178-44

Morphine
Sulfate Injection, USP

10 mg/mL

FOR SC, IM OR SLOW IV USE
NOT FOR EPIDURAL OR INTRATHECAL USE

25 x 1 mL DOSETTE® Vials

Baxter **ESILEDERLE™**

Mfd. for an affiliate of **Baxter Healthcare Corporation**
Deerfield, IL 60015 USA
by: Elkins-Sinn, Cherry Hill, NJ 08003 400-830-01

Each mL contains: morphine sulfate 10 mg, monobasic sodium phosphate, monohydrate 10 mg, dibasic sodium phosphate, anhydrous 2.8 mg, sodium formaldehyde sulfoxylate 3 mg and phenol 2.5 mg in Water for Injection. pH 2.5-6.5; sulfuric acid added, if needed, for pH adjustment. Sealed under nitrogen.

Usual Dosage: See package insert. **PROTECT FROM LIGHT.**

Store at 15°-30°C (59°-86°F). Avoid freezing.

NOTE: Do not use if color is darker than pale yellow, if it is discolored in any other way or if it contains a precipitate.

DOSETTE® is a registered trademark of A.H. Robins Company.

NDC 0641-6006-10

Atropine
Sulfate Injection, USP

8 mg/20 mL (0.4 mg/mL)

FOR IM, IV OR SC USE

10 x 20 mL Multiple Dose Vials

Manufactured by:
WEST-WARD
Easton, NJ 07724 USA
462-422-01

Each mL contains: Atropine Sulfate 0.4 mg; Benzyl Alcohol 9 mg; Sodium Chloride 9 mg; Water for Injection qs; pH is adjusted with Sulfuric Acid if necessary. pH 3.0-6.5.

Usual Dosage: See package insert.

Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].

LOT: _____ EXP: _____

The United States Pharmacopeia (USP) and National Formulary (NF) are the official standards for all prescription and over-the-counter medicines, dietary supplements, excipients and other healthcare products manufactured and sold in the United States.

Important:

- Medication with similar names may have markedly different chemical structures and actions

Examples: buspirone (BuSpar)-antianxiety medication

bupropion (Wellbutrin)-treats major depressive disorders

Generic names might be similar but the action, composition of the medication are different.


Food and Drug Administration (FDA) requires the use of “tall-man” letters in generic names that are associated with errors

bus**P**IRone and bu**P**RO**P**ion

Accronym USP

Do not confuse the acronym with USP and NF with other abbreviations that designate a special form of a medication, like **CR** which means control release.

Safety Alert* use caution with medication that have similar spelling.



Trade Name

- Referred as “brand name or proprietary name
- Manufacturer's name for the medication
- Brand name is prominent on the label and capitalized
- Medication can have multiple trade names
- Identified by the (R) which is the registration symbol

Registration Symbol

Trade name

Generic Name

©Abbott

6

NDC 0074-6122-90

Do not accept if seal over bottle opening is broken or missing.
Dispense in a USP tight container.
Each tablet contains: 48 mg fenofibrate.
See package insert for prescribing information.
Store at 25°C (77° F); excursions permitted to 15-30°C (59-86° F) [see USP Controlled Room Temperature].
Protect from moisture.
Manufactured for Abbott Laboratories North Chicago, IL 60064, U.S.A. by Fournier Laboratories Ireland Limited Anngrove, Carrigtwohill Co. Cork, Ireland Product of France.

3 00746 12290

TriCor[®]

Fenofibrate Tablets

48 mg

90 Tablets

Exp. Lot DN1080Y2

Rx only

Abbott

Trade name

TM –name given by the manufacturer and can not be used by another company

Trademark for that company

IsentressTM
(raltegravir) tablets
400 mg

Each tablet contains 434.4 mg raltegravir potassium, equivalent to 400 mg raltegravir.

Rx only
60 Tablets

227

NDC 0006-0227-61
Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F). See USP Controlled Room Temperature.
USUAL ADULT DOSAGE:
See accompanying circular.

MERCK & CO., INC.
Whitehouse Station, NJ 08889, USA
Raltegravir potassium (active ingred.)
Made in Ireland
Formulated in USA

9794800

Dosage Strength

Refers to weight or amount of the medication provided in a specific unit of measure

Ex.(Weight per tablet, capsule, milliliter.)

Solid forms-the amount of medication per tablet, capsule, or other form.





Liquid form-medication present in a certain amount solution.

Can be expressed in different systems of measure

Ex. Apothecary and metric measures

Some oral liquids may state household measures: ex. Each 15 ml (one tablespoon) contains 80 mg.

Dosage strength per tablet (weight and specific unit of measurement)


<p>Exp. Lot DN1080V2</p> <p>©Abbott</p> <p>3 0074612290 6</p>	<p>NDC 0074-6122-90</p> <p>TriCor[®] Fenofibrate Tablets</p> <p>48 mg</p> <p>90 Tablets</p> <p>Rx only</p>  	<p>Do not accept if seal over bottle opening is broken or missing. Dispense in a USP tight container. Each tablet contains: 48 mg fenofibrate. See package insert for prescribing information. Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture. Manufactured for Abbott Laboratories North Chicago, IL 60064, U.S.A. by Fournier Laboratories Ireland Limited Anngrove, Carrigtwohill Co. Cork, Ireland Product of France.</p>	<p>Isentress[™] (raltegravir) tablets</p> <p>400 mg</p> <p>Each tablet contains 434.4 mg raltegravir potassium, equivalent to 400 mg raltegravir.</p> <p>Rx only</p> <p>60 Tablets</p> 	<p>NDC 0006-0227-61</p> <p>Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F). See USP Controlled Room Temperature.</p> <p>USUAL ADULT DOSAGE: See accompanying circular.</p> <p> MERCK & CO., INC. Whitehouse Station, NJ 08889, USA</p> <p>Raltegravir potassium (active ingred.) Made in Ireland</p> <p>Formulated in USA</p> <p>9794800</p>
---	--	---	---	--

Namenda (oral solution)

Dosage strength


Rx only NDC 0456-3202-12

Namenda
memantine HCl
oral solution




2 mg/mL


12 fl oz (360 mL)




Namenda
memantine HCl
oral solution



Keep this and all drugs out of the reach of children.
Dispense in a tightly closed container as described in the USP.
Store at 25°C (77°F) –
Excursions permitted to 15°C to 30°C (59°F to 86°F)
[see USP Controlled Room Temperature]
See package insert for dosing and full prescribing information.
Licensed from Merz & Co., GmbH & Co.



0456-3202-12 4

 **FOREST PHARMACEUTICALS, INC.**
SuOnClary of Forest Laboratories, Inc.
St. Louis, Missouri 63045

RMC 6175 05/05

(Oral solution)-two different but equivalent dosage strengths

Do Not Use For Reconstitution If
Printed  Neckband Is Missing Or Broken

NDC 0003-0681-44 **100 mL**

EQUIVALENT TO
125 mg (200,000 units)
per 5 mL when reconstituted
according to directions.

VEETIDS®
Penicillin V Potassium
For Oral Solution, USP

Rx only

To the Pharmacist: Prepare solution at time of dispensing. Add to the bottle a total of 61 mL of water. For ease in preparation, add the water in 2 portions. Shake well after each addition. This provides 100 mL of solution. Each 5 mL contains penicillin V potassium equivalent to 125 mg (200,000 units) of penicillin V.

READ ACCOMPANYING CIRCULAR
APOTHECON®
A Bristol-Myers Squibb Co.
Princeton, NJ 08540 USA
750644DCCL-3 53-006526-02

PULL DOWN TAB TO OPEN BOOKLET ▲

Control:
Exp. Date
of Powder:

Dosage expressed as Ratio or Percent

Epinephrine contains 1 g of medication per 1,000 mL solution (1:1,000) and 1 mg per mL

Lidocaine 1% contains 1 g of medication per 100 mL solution and 10 mg per mL

NDC 0517-1071-25
EPINEPHRINE
INJECTION, USP **1:1000** (1 mg/mL)

1 mL AMPULE
FOR SC AND IM USE. FOR IV
AND IC USE AFTER DILUTION.

Rx Only
CONTAINS NO SULFITES.
PRESERVATIVE FREE.

Store at controlled room temperature
up to 25°C (77°F) (See USP). Rev. 1/04

AMERICAN REGENT, INC.
SHIRLEY, NY 11967

NDC 10019-017-56

Lidocaine 1%
HCl Injection, USP

(10 mg/mL) **Rx only**

FOR INFILTRATION AND NERVE BLOCK
NOT FOR SPINAL OR EPIDURAL ANESTHESIA

30 mL Multiple Dose Vial

Baxter **ESILEDERLE™**
Mfd. for Baxter Healthcare Corporation affiliate
by: Elkins-Sinn, Cherry Hill, NJ 08003 400-741-01

Each mL contains lidocaine hydrochloride 10 mg, sodium chloride 7 mg and methylparaben 1 mg in Water for Injection. pH 5.0-7.0; sodium hydroxide and/or hydrochloric acid used, if needed, for pH adjustment.

Usual Dosage: See package insert for complete prescribing information.

Store at controlled room temperature 15°-30°C (59°-86°F).

Lot: Exp.:



Safety Alert*

- The **Institute for Safe Medication Practices (ISMP)** recommends that the **slash mark (/) not be used to separate two doses to indicate per because it can be misread and mistaken as the number 1.** Use per rather than the slash mark.

Example: Use 10 mg per 5 mL rather than 10 mg/5 mL, which could be misread as 10 mg and 15 mL.

Read medication carefully to avoid errors.

- Medications can be deceptively similar but not necessarily similar in action.
- Inderal and Inderide > similar names > but action and content different

Form

Specifies the type of preparation available in the package

- Examples: tablets, capsules, liquids, suppositories, and ointments.
- Solutions may be by milliliters (mL)
- Some may be available in powder form, patches, or granular form

Labels may indicate abbreviations or words that describe the form

example: **CR** (controlled release), **LA** (long acting), **DS** (double Strength), **SR** (sustained release), **XL** (long acting), **ES** (extra strength),

Other abbreviations **EC (enteric coated)** or just indicate enteric coated.

(THIS MEDICATION SHOULD NOT BE CRUSHED)

Abbreviations that describe the form of a medication prepared to allow **extended action**, or **slow release** of active ingredients

- Examples: Procardia XL, Inderal LA, Calan SR, and Metformin extended release.

(THIS SPECIAL FORMS SHOULD BE SWALLOW WHOLE AND NEVER BE CRUSHED!)

A

NDC 0093-7212-01
METFORMIN HYDROCHLORIDE
Extended-release Tablets
750 mg

Each extended-release tablet contains: Metformin Hydrochloride 750 mg

R_x only

100 TABLETS

TEVA

Usual Dosage: See package insert for full prescribing information.
 Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
 Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. ISS: 10/2004
 TEVA PHARMACEUTICAL, INC. LTD., Jerusalem, 91010, Israel
 Manufactured For: TEVA PHARMACEUTICALS USA Sellersville, PA 18960
 323K214000105 0093-7212-01

B

NDC 0074-6114-13
100 Sprinkle Capsules

DEPAKOTE[®]
SPRINKLE CAPSULES

DIVALPROEX SODIUM COATED PARTICLES IN CAPSULES

125 mg Valproic Acid Activity

R_x only

6505-01-327-8510
 Do not accept if seal over bottle opening is broken or missing.
 Dispense in a USP tight, light-resistant container. Opaque white and blue capsule bears THIS END UP and DEPAKOTE[®] SPRINKLE and 125 mg for product identification.
 Each capsule contains: Divalproex sodium equivalent to valproic acid 125 mg
 Capsule may be swallowed whole or opened and contents placed on food for administration. See enclosure for prescribing information.
 U.S. Pat. No. 4,988,731
 ©Abbott
 Abbott Laboratories
 North Chicago, IL 60064 U.S.A.

C

NDC 24090-470-88 100 Capsules

Inderal[®] LA
(propranolol hydrochloride)
Long-Acting Capsules
60 mg

SEALED FOR YOUR PROTECTION

R_x only

AKRIMAX
 PHARMACEUTICALS

Each long-acting capsule contains 60 mg of propranolol hydrochloride.
 Usual Dosage: See accompanying descriptive literature.
 Manufactured by Akrimax Pharmaceuticals, LLC, Chantler, NJ 07018
 By Wyeth Pharmaceuticals, Philadelphia, PA 19101
 Marketed and Distributed by Akrimax Pharmaceuticals, LLC, Chantler, NJ 07018
 944002657 9847M200 Rev. 01/08

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature].
 Protect from light, moisture, freezing, and excessive heat.
 Dispense in a tight, light-resistant container as defined in the USP.

D

Do not accept if seal over bottle opening is broken or missing.
 Store below 86°F (30°C).
 Dispense in a USP tight container. Keep tightly closed.

NDC 0074-6320-53
500 Tablets

ERY-TAB[®]

ERYTHROMYCIN DELAYED-RELEASE TABLETS, USP
 ENTERIC-COATED

333 mg

R_x only

Each tablet contains: Erythromycin 333 mg as the free base.
 Usual Dosage: For full prescribing information see package insert.
 DOSAGE MAY BE ADMINISTERED WITHOUT REGARD TO MEALS.
 ©Abbott
 U.S. Pat. No. 4,340,582
 Abbott Laboratories
 North Chicago, IL60064, U.S.A.


Safety Alert*

- ❑ Certain forms should not be crushed or dissolved for use through a nasogastric, gastrostomy, or jejunostomy tube without first consulting a pharmacist or medication guide for information regarding whether a medication can be crushed or altered.
- ❑ May results in an alteration of the medications action and cause unintended outcomes.






shutterstock.com • 337265087



INTRAMUSCULAR INJECTION



Route of administration

- Describes how the medication is to be administered.
- Examples: oral, enteral (into the gastrointestinal tract through a tube), sublingual, injection (IV, IM, subQ), optical, topical, and others.

Optical and Topical administration





Read labels carefully for administration route.

PROFESSIONAL SAMPLE – NOT FOR SALE

3.5g 50 metered inhalations

AEROBID®
(flunisolide)
Inhaler System

FOR ORAL INHALATION ONLY

Rx Only

mfd for
FOREST PHARMACEUTICALS, INC.
Subsidiary of Forest Laboratories, Inc.
St. Louis, Missouri 63045

Shake Well Before Using. 769500

Contains flunisolide as the hemihydrate suspended in propellants (trichloromonofluoromethane, dichlorodifluoromethane and dichlorotetrafluoroethane) with sorbitan trioleate as a dispersing agent. Each activation delivers approximately 250 mcg flunisolide to the patient.

Usual Dose: See package insert for dosing information.

Store at 25°C (77°F) (see insert)

CONTENTS UNDER PRESSURE. Do not puncture. Do not use or store near heat or open flame. Exposure above 120°F (49°C) may cause container to burst. Never throw container into fire or incinerator.

Keep out of reach of children.

mfd by 3M Pharmaceuticals St. Paul, MN 55133 Rev. 7/03

NO VA DRUGS

SAMPLE. FOR EDUCATIONAL PURPOSES ONLY

Exp. Date

Total Volume:

- Refers to the quantity contained in a bottle, vial, or ampule.
- Found in labels of solutions for injections or oral liquids.

There have been documented medication errors caused by misinterpretation of dosage strength and total volume. The Food and Drug Administration (FDA) has required that the dosage strength per total volume be the prominent expression on single and multidose injectable product labels, followed in close proximity by the dosage strength per mL enclosed in parentheses

Dosage strength

Dosage strength for entire vial

NDC 63323-282-04 28204

CLINDAMYCIN
INJECTION, USP
600 mg/4 mL
(150 mg/mL)*
4 mL Single Dose Vial
Rx only

Sterile
*Each mL contains clindamycin phosphate equivalent to 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol as a preservative. When necessary, pH adjusted with sodium hydroxide and/or hydrochloric acid.
Usual Dosage: See package insert.
Warning: If given intravenously, must be diluted before use.
Store at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature].
Do not refrigerate.
Vial stoppers do not contain natural rubber latex.

Abraxis
Pharmaceutical Products
Schaumburg, IL 60173

402129A

LOT/EXP

3 63323-282-04 2


Safety Alert*

- recognize the difference between the amount per milliliter and the total volume to avoid confusion and errors.
- Do not confuse total volume, total amount in container with dosage strength.

Total volume?


dosage strength?


Rx only NDC 0456-3202-12

Namenda 
memantine HCl
oral solution


2 mg/mL


12 fl oz (360 mL)



Namenda
memantine HCl
oral solution 

Keep this and all drugs out of the reach of children.
Dispense in a tightly closed container as described in the USP.
Store at 25°C (77°F) – Excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]
See package insert for dosing and full prescribing information.
Licensed from Merz & Co., GmbH & Co.


N 0456-3202-12 4

 **FOREST PHARMACEUTICALS, INC.**
Subsidiary of Forest Laboratories, Inc.
St. Louis, Missouri 63045


RMC 6175 05/05

Total volume?

Dosage strength?

Rx only NDC 0456-3202-12


Namenda
memantine HCl
oral solution




2 mg/mL

12 fl oz (360 mL)

Namenda
memantine HCl
oral solution



Keep this and all drugs out of the reach of children.
Dispense in a tightly closed container as described in the USP.
Store at 25°C (77°F) – Excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]
See package insert for dosing and full prescribing information.
Licensed from Merz & Co., GmbH & Co.



0456-3202-12 4

FOREST PHARMACEUTICALS, INC.
Subsidiary of Forest Laboratories, Inc.
St. Louis, Missouri 63045

RMC 6175 05/05

Total amount in container

- For solid forms of medication, such as tablets or capsules, the total amount is the total number of tablets or capsules in the container.
- The dosage strength, as well as the total amount in the container, is included on labels of solid forms of medication, such as tablets or capsules. (the dosage strength is 48 mg per tablet.)

©Abbott

NDC 0074-6122-90

Do not accept if seal over bottle opening is broken or missing. Dispense in a USP tight container. Each tablet contains: 48 mg fenofibrate. See package insert for prescribing information. Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture. Manufactured for Abbott Laboratories North Chicago, IL 60064, U.S.A. by Fournier Laboratories Ireland Limited Anngrove, Carrigtwohill Co. Cork, Ireland Product of France.

TriCor[®]
Fenofibrate
Tablets

48 mg

90 Tablets

Rx only

Abbott

Exp. Lot DN1080V2

3 00746 12290 6

LOT: 00746122906

(dosage strength is 750 mg per extended-release tablet.)

NDC 62037-577-01

750 mg

Each Extended-Release Tablet Contains: Metformin Hydrochloride, USP 750 mg

Dispense in a light-resistant container. Usual Dosage: See enclosed package insert for dosage information. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Metformin Hydrochloride
Extended-Release
Tablets, USP

100 Tablets
Rx Only

Manufactured by: Watson Pharma Private Limited, Verna, Salcete Goa-403 722 INDIA. Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA. Rev. 02/16

Actavis

LOT: 6203757701

231168

Directions for Mixing or Reconstituting a Medication

When medication comes in a powdered form, the directions for how to mix or reconstitute it and with what solution are found on the label or package insert. The directions for reconstitution should be followed exactly as stated on the label for accuracy in administration.



NDC 0093-4150-80

AMOXICILLIN

for Oral Suspension USP

equivalent to
125 mg per 5 mL
amoxicillin when reconstituted according to directions.

Usual Dosage: Adults — 250 mg - 500 mg every eight hours, depending on type and severity of infection.
Children — 20 mg - 40 mg/kg/day in divided doses every eight hours, depending on type and severity of infection.

Rx only
See accompanying literature.
WARNING: NOT FOR INJECTION

150 mL (when mixed)

TEVA

Amoxicillin trihydrate equivalent to 3.75 g amoxicillin. Store dry powder at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

TO THE PHARMACIST: Prepare suspension at time of dispensing. Add to the bottle a total of 113 mL of water. For ease in preparation, tap bottle to loosen powder, add the water in two portions, shaking well after each addition. The resulting suspension will contain amoxicillin trihydrate equivalent to 125 mg amoxicillin in each 5 mL (teaspoonful).

Oversized bottle permits shaking space.

IMPORTANT
When stored at room temperature or in refrigerator discard unused portion of reconstituted suspension after 14 days.

Date of reconstitution:


Shake well before using. Keep tightly closed.

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Manufactured in Canada By:
NOVOPHARM LIMITED
Toronto, Canada M1B 2K9

Manufactured For:
TEVA PHARMACEUTICALS USA
Sellersville, PA 18960

N 0093-4150-80
3



Rev. E 7/2005

CYTARABINE

FOR INJECTION USP

NDC 55390-132-10

LYOPHILIZED

See package insert for complete prescribing information.

Each vial contains 500 mg and, if necessary, hydrochloric acid and/or sodium hydroxide for pH adjustment.

When reconstituted with 10 mL Bacteriostatic Water for Injection USP with benzyl alcohol, each mL contains 50 mg cytarabine. **Do not use a diluent containing benzyl alcohol for intrathecal and high dose investigational use.**

Store both powder and reconstituted solution at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Use reconstituted solution within 48 hours. Discard solution if a slight haze develops.


Manufactured for:
Bedford Laboratories™
Bedford, OH 44146


CYB-VB06



FOR INTRAVENOUS, SUBCUTANEOUS, OR INTRATHECAL USE

500 mg

Rx ONLY





Multiple-Dose Vial
20 mL (100 mg/mL)

Sterile Aqueous Injection 10%

Demerol[®]
meperidine
hydrochloride
injection, USP


**Warning: May be
habit forming.**

100 mg/mL

Rx only

08-8638-2/R1-4/98

Abbott Laboratories
N. Chicago, IL 60064, USA



NDC 0074-1940-63
240 mL

NORVIR[®]
(RITONAVIR ORAL
SOLUTION)

80 mg per mL

Shake well before each use.
DO NOT REFRIGERATE

Use by product expiration date.

 Rx only 02-8410-2/R4

ALERT
Find out about medicines
that should **NOT** be taken
with **NORVIR**.

**Note to Pharmacist: Do not cover ALERT
box with pharmacy label.**



Precautions

*Medications may come with warnings, alerts, or precautions that are related to safety, effectiveness, or administration considerations and need to be followed.

- **Storage alerts**
- **Shake well**
- **Protect from light**
- **May be habit forming**
- **Keep tightly closed**
- **Not for injection**
- **Caution not to take with other medication**

Expiration Date:

- Medication labels contain information such as the expiration date (which may be indicated with the abbreviation **Exp**)
- Expiration dates indicate the last date on which a medication should be used.
- Imperative to check expiration dates routinely
- If expired, medication may lose its potency or cause adverse or different effects from the intended
- Discard expired medication according to agency policy
- Narcotic disposal must be witnessed by another nurse
- Never give expired medication to patients
- Patient education in all aspects of medication administration



NDC 63323-280-02 28002
FUROSEMIDE
INJECTION, USP
20 mg/2 mL
(10 mg/mL)
For IM or IV Use Rx only
2 mL Single Dose Vial
Preservative Free
Discard unused portion.
PROTECT FROM LIGHT.
Do not use if discolored.
Abraxis
Pharmaceutical Products
Schaumburg, IL 60173

401803C

LOT/EXP 8/2012



3 63323-280-02 4

Medication Labels for Combined Medications

- medication labels may indicate that a medication contains two or more medications
- Combination medications are sometimes ordered by the number of tablets, capsules, or milliliters to be given rather than by the dosage strength.
- Combined medications can not be ordered without a specific dosage. Some medications come in different strengths. **It must include the dosage!**
- **Example: Sinemet 25 mg/100 mg, 1 tab po tid.**



DUPONT PHARMA
SINEMET®
(CARBIDOPA-
LEVODOPA)

25-100

NDC 0056-0650-68
3365/7826102
7783/HC

100 TABLETS

Each tablet contains:
Carbidopa 25 mg*
*(Anhydrous equivalent)
Levodopa 100 mg

Marketed by:
DuPont Pharma
Wilmington, DE 19880

Manufactured by:
MERCK & CO., Inc.
WEST POINT, PA 19486, USA

USUAL ADULT DOSAGE: See accompanying circular.
Dispense in a well-closed container.
This is a bulk package and not intended for dispensing.
CAUTION: Federal (USA) law prohibits dispensing without prescription.
SINEMET is a registered trademark of MERCK & CO., Inc.

Lot _____

Exp. _____



DUPONT PHARMA
SINEMET®
(CARBIDOPA-
LEVODOPA)

10-100

NDC 0056-0647-68
3346/7826602
7784/HC

100 TABLETS

Each tablet contains:
Carbidopa 10 mg*
*(Anhydrous equivalent)
Levodopa 100 mg

Marketed by:
DuPont Pharma
Wilmington, DE 19880

Manufactured by:
MERCK & CO., Inc.
WEST POINT, PA 19486, USA

USUAL ADULT DOSAGE: See accompanying circular.
PROTECT FROM LIGHT. Dispense in a well-closed, light-resistant container. This is a bulk package and not intended for dispensing.
CAUTION: Federal (USA) law prohibits dispensing without prescription.
SINEMET is a registered trademark of MERCK & CO., Inc.

Lot _____

Exp. _____

CR indicates controlled release or sustained release tablet. The dosage strength of carbidopa is 50 mg, and that of levodopa is 200 mg

DU PONT SINEMET[®] CR
(CARBIDOPA-LEVODOPA,
SUSTAINED-RELEASE) **50-200**

Each tablet contains:
Carbidopa 50 mg*
*(Anhydrous equivalent)
Levodopa 200 mg

USUAL ADULT DOSAGE: See accompanying circular.
Tablets should be swallowed without chewing or crushing.
Avoid temperatures above 30°C (86°F).
CAUTION: Federal (USA) law prohibits dispensing without prescription.
This is a bulk package and not intended for dispensing. 3570/7753703
SINEMET is a registered trademark of MERCK & CO., Inc. 7B59/EB

100 TABLETS

NOC 0056-0521-28 NSN 6505-01-343-3483

Example:

Percocet, which is used to treat moderate to severe pain, is a combination of oxycodone (narcotic pain reliever) and acetaminophen (non-narcotic pain reliever). The medication contains varying strengths of oxycodone (2.5 mg to 10 mg) and acetaminophen (325 mg to 650 mg). Orders for this medication must specify the dosage strength. Example: Percocet 10 mg/325 mg, 1-2 tabs p.o. q6h prn for pain.

:



Example:

Septra, an antibacterial that is also manufactured under the trade name Bactrim, is a combination of trimethoprim and sulfamethoxazole. Septra tablet contains 80 mg of trimethoprim and 400 mg of sulfamethoxazole. A Septra DS (double-strength) tablet contains 160 mg of trimethoprim and 800 mg of sulfamethoxazole.

100 Tablets NDC 0173-0852-55

SEPTRA® TABLETS
(trimethoprim and sulfamethoxazole)

Each scored tablet contains
80 mg trimethoprim and
400 mg sulfamethoxazole.

CAUTION: Federal law prohibits
dispensing without prescription.

Glaxo Wellcome Inc.
Research Triangle Park, NC 27709
Rev. 2/96 **596154**

LOT
EXP

6505-00-501-6452

For indications, dosage, precautions, etc., see
accompanying package insert.
Store at 15° to 25°C (59° to 77°F) in a dry place.
Dispense in a tight, light-resistant container as
defined in the U.S.P.
Made in U.S.A. U.S. Patent No. 4,209,513 (tablet)

3 0173-0852-55 7

100 Tablets NDC 0173-0853-55

SEPTRA® DS
Double Strength
(trimethoprim and
sulfamethoxazole)

Each scored tablet contains
160 mg trimethoprim and
800 mg sulfamethoxazole.

CAUTION: Federal law prohibits
dispensing without prescription.
U.S. Patent No. 4,209,513 (Tablet)

Glaxo Wellcome Inc.
Research Triangle Park, NC 27709
595493

LOT
EXP

6505-01-016-1470 Rev. 5/96

Store at 15° to 25°C (59° to 77°F) in a dry place.
Dispense in tight, light-resistant container as defined in the
U.S.P.
For indications, dosage, precautions, etc., see accompanying
package insert.
Made in U.S.A.

3 0173-0853-55 4

Unit-Dose Packaging

- Most medication in hospitals are available in unit dose.
- 24-hour supply for each patient
- Individually wrapped packets that are labeled for individualized dosage for specific clients
- label on the package includes generic and trade names, manufacturer, lot number, and expiration date
- The nurse must read the label on unit-dose packages and note that sometimes, even with this method, calculation may be necessary.



BLACK BOX WARNING




**WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS
WITH DEMENTIA-RELATED PSYCHOSIS**

See full prescribing information for complete boxed warning.


**Elderly patients with dementia-related psychosis treated with
antipsychotic drugs are at an increased risk of death. RISPERDAL[®] is
not approved for use in patients with dementia-related psychosis. (5.1)**




**MY
ACCUTANE
JOURNEY**



Accutane (isotretinoin) Side Effects on the Fetus



- Ear deformities
- Microcephaly
- Brain fluid accumulation
- Abnormal immune system development
- Learning disabilities
- Facial deformities
- Heart abnormalities



Medication Information

To decrease errors and manage the risks of medications and adverse medication effects, the U.S. Food and Drug Administration (FDA) mandates the format in which medication information is provided on Prescription Medication Package Inserts.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ZYPREXA safely and effectively. See full prescribing information for ZYPREXA.

ZYPREXA (olanzapine) Tablet for Oral use
ZYPREXA ZYDIS (olanzapine) Tablet, Orally Disintegrating for Oral use
ZYPREXA IntraMuscular (olanzapine) Injection, Powder, For Solution for Intramuscular use

Initial U.S. Approval: 1996

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

- See full prescribing information for complete boxed warning.
- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ZYPREXA is not approved for the treatment of patients with dementia-related psychosis. (5.1, 5.14, 17.2)
- When using ZYPREXA and fluoxetine in combination, also refer to the Boxed Warning section of the package insert for Symbyax.

RECENT MAJOR CHANGES

Indications and Usage:

Schizophrenia (1.1)	12/2009
Bipolar I Disorder (Manic or Mixed Episodes) (1.2)	12/2009
Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder (1.3)	12/2009
ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania (1.4)	12/2009

Dosage and Administration:

Schizophrenia (2.1)	12/2009
Bipolar I Disorder (Manic or Mixed Episodes) (2.2)	12/2009

Warnings and Precautions:

Orthostatic Hypotension (5.8)	05/2010
Leukopenia, Neutropenia, and Agranulocytosis (5.9)	08/2009
Hyperprolactinemia (5.15)	01/2010

INDICATIONS AND USAGE

ZYPREXA® (olanzapine) is an atypical antipsychotic indicated:

As oral formulation for the:

- Treatment of schizophrenia. (1.1)
 - Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. (14.1)
 - Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1). The increased potential (in adolescents compared with adults) for weight gain and hyperlipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.1)
- Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. (1.2)
 - Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. (14.2)
 - Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder (14.2). The increased potential (in adolescents compared with adults) for weight gain and hyperlipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.2)
- Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. (1.3)
 - Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. (1.2)
 - Efficacy was established in two 6-week clinical trials in adults (14.2). Maintenance efficacy has not been systematically evaluated.

As ZYPREXA IntraMuscular for the:

- Treatment of acute agitation associated with schizophrenia and bipolar I mania. (1.4)

- Efficacy was established in three 1-day trials in adults. (14.3)

As ZYPREXA and Fluoxetine in Combination for the:

- Treatment of depressive episodes associated with bipolar I disorder (1.5)
 - Efficacy was established with Symbyax (olanzapine and fluoxetine combination) in adults; refer to the product label for Symbyax
- Treatment of treatment resistant depression (major depressive disorder) in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode (1.6)
 - Efficacy was established with Symbyax (olanzapine and fluoxetine combination) in adults; refer to the product label for Symbyax

DOSAGE AND ADMINISTRATION

Schizophrenia in adults (2.1)	Oral: Start at 5-10 mg once daily Target: 10 mg/day within severe
Schizophrenia in adolescents (2.1)	Oral: Start at 2.5-5 mg once daily Target: 10 mg/day
Bipolar I Disorder (manic or mixed episodes) in adults (2.2)	Oral: Start at 10 or 15 mg once daily
Bipolar I Disorder (manic or mixed episodes) in adolescents (2.2)	Oral: Start at 2.5-5 mg once daily Target: 10 mg/day
Bipolar I Disorder (manic or mixed episodes) with lithium or valproate in adults (2.2)	Oral: Start at 10 mg once daily
Agitation associated with Schizophrenia and Bipolar I Mania in adults (2.4)	IM: 10 mg (5 mg or 7.5 mg when clinically warranted) Assess for orthostatic hypotension prior to subsequent dosing (max doses 2-4 hrs apart)
Depressive Episodes associated with Bipolar I Disorder in adults (2.5)	Oral in combination with fluoxetine Start at 5 mg of oral olanzapine 20 mg of fluoxetine once daily
Treatment Resistant Depression in adults (2.6)	Oral in combination with fluoxetine Start at 5 mg of oral olanzapine 20 mg of fluoxetine once daily

- Lower starting dose recommended in debilitated or pharmacodynamically sensitive patients or patients with predisposition to hypotensive reactions, or with potential for slowed metabolism
- Olanzapine may be given without regard to meals. (2.1)

ZYPREXA and Fluoxetine in Combination:

- Dosage adjustments, if indicated, should be made with the individual components according to efficacy and tolerability. (2.5, 2.6)
- Olanzapine monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder or treatment resistant depression. (2.5, 2.6)
- Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated. (2.5, 2.6)

DOSAGE FORMS AND STRENGTHS

- Tablets (not scored): 2.5, 5, 7.5, 10, 15, 20 mg (3)
- Orally Disintegrating Tablets (not scored): 5, 10, 15, 20 mg (3)
- Intramuscular Injection: 10 mg vial (3)

CONTRAINDICATIONS

- None with ZYPREXA monotherapy.
- When using ZYPREXA and fluoxetine in combination, also refer to the Contraindications section of the package insert for Symbyax®. (4)
- When using ZYPREXA in combination with lithium or valproate refer to the Contraindications section of the package inserts for those products. (4)

WARNINGS AND PRECAUTIONS

- Elderly Patients with Dementia-Related Psychosis:** Increased risk of death and increased incidence of cerebrovascular adverse events (stroke, transient ischemic attack). (5.1)
- Suicide:** The possibility of a suicide attempt is inherent in schizophrenia and in bipolar I disorder, and close supervision of high-risk patients should accompany drug therapy; when used in combination with fluoxetine, also refer to the Boxed Warning and Warnings and Precautions sections of the package insert for Symbyax. (5.2)
- Neuroleptic Malignant Syndrome:** Manage with immediate discontinuation and close monitoring. (5.3)

Drug Facts

Do not use ● if you have ever had an allergic reaction to any other pain reliever/fever reducer ● right before or after heart surgery

Ask a doctor before use if ● the stomach bleeding warning applies to you ● you have a history of stomach problems, such as heartburn ● you have high blood pressure, heart disease, liver cirrhosis, or kidney disease ● you are taking a diuretic ● you have problems or serious side effects from taking pain relievers or fever reducers ● you have asthma

Ask a doctor or pharmacist before use if you are ● under a doctor's care for any serious condition ● taking any other drug

When using this product ● take with food or milk if stomach upset occurs ● the risk of heart attack or stroke may increase if you use more than directed or for longer than directed

Stop use and ask a doctor if

● you experience any of the following signs of stomach bleeding:
● feel faint ● vomit blood ● have bloody or black stools
● have stomach pain that does not get better
● pain gets worse or lasts more than 10 days ● fever gets worse or lasts more than 3 days ● you have difficulty swallowing ● it feels like the pill is stuck in your throat ● redness or swelling is present in the painful area ● any new symptoms appear

If pregnant or breast-feeding, ask a health professional before use. It is especially important not to use naproxen sodium during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Directions ● do not take more than directed ● the smallest effective dose should be used ● drink a full glass of water with each dose ● do not take longer than 10 days, unless directed by doctor (see Warnings)

Drug Facts

Active ingredient (in each caplet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)*Pain reliever/fever reducer
Purposes
*nonsteroidal anti-inflammatory drug

Uses

● temporarily relieves minor aches and pains due to:
● minor pain of arthritis
● muscular aches ● backache
● menstrual cramps ● headache
● toothache ● the common cold
● temporarily reduces fever

Warnings

Allergy alert: Naproxen sodium may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:
● hives ● facial swelling ● asthma (wheezing)
● shock ● skin reddening ● rash ● blisters
If an allergic reaction occurs, stop use and seek medical help right away.

Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you:
● are age 60 or older ● have had stomach ulcers or bleeding problems ● take a blood thinning (anticoagulant) or steroid drug ● take other drugs containing prescription or nonprescription NSAIDs (aspirin, ibuprofen, naproxen, or others) ● have 3 or more alcoholic drinks every day while using this product
● take more or for a longer time than directed

ALL DAY STRONG
ALEVE®

naproxen sodium tablets, 220 mg (NSAID)
Pain reliever/fever reducer



TO OPEN
PUSH IN TAB AND PULL OUT

STRENGTH TO LAST ALL DAY

Drug Facts

Adults and children 12 years and older
● take 1 caplet every 8 to 12 hours while symptoms last
● for the first dose you may take 2 caplets within the first hour
● do not exceed 2 caplets in any 8- to 12-hour period
● do not exceed 3 caplets in a 24-hour period

Children under 12 years
● ask a doctor

Other information ● each caplet contains: sodium 20 mg ● store at 20-25°C (68-77°F). Avoid high humidity and excessive heat above 40°C (104°F).

Inactive ingredients FD&C blue #2 lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, talc, titanium dioxide

Questions or comments?
1-800-389-0689 (Mon-Fri 9AM-5PM EST) or
www.aleve.com

Do not use if carton is open or if foil seal imprinted with "SAFETY SQUASHT" on bottle opening is missing or broken.

Roche HealthCare LLC
234 Bldg 1710
Nutley, NJ 07110-1700 USA
MADE IN GERMANY
Aleve is a trademark of Roche.

Safety Squasht is a registered trademark of Procter & Gamble Corp. Used with permission.

Over-the-Counter (OTC) Labels

Medications that the client can purchase without a prescription.

Review of medication labels

The National Drug Code is a unique product identifier used in the United States for drugs intended for human use

NDC number — NDC 10019-941-71

Generic name — **Methotrexate Injection, USP**

Dosage strength — **250 mg (25 mg/mL)**

Total volume — **10 mL Vial** **Rx only**

CONTAINS PRESERVATIVE

NOT FOR INTRATHECAL USE

Mfd. for **Baxter Healthcare Corp.** affiliate
by: Bigmar Pharmaceuticals SA
Barbengo, Switzerland

Usual Dosage: Consult package insert for dosage and full prescribing information.
Each mL contains methotrexate sodium equivalent to 25 mg methotrexate. **Preservative: Benzyl Alcohol 0.90% w/v.**
Inactive ingredients: Sodium Chloride 0.26% w/v and Water for Injection. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH to 8.5-8.7 during manufacture.
Store at controlled room temperature 15°-30°C (59°-86°F). PROTECT FROM LIGHT. Retain in carton until time of use. Discard any unused portion.

WARNING: SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION AND BOXED WARNINGS. 10-1032A 460-232-00

Lot: Exp. Date:

Alert (warning)

NDC (National Drug Code number)
0009-0010-37

Upjohn
NDC 0009-0010-37
10 Tablets

Halcion[®] **C_{iv}**
Tablets

triazolam
tablets, USP

0.125mg

Caution: Federal law prohibits dispensing without prescription.

Barcode: 0009-0010-37 9

Total amount in container: 10 tablets

Trade name (brand name): Halcion

Barcode

Generic name: triazolam

USP (United States Pharmacopeia)
National Drug Listing

Form: tablets

Dosage strength: 0.125 mg per tablet

Controlled substance
schedule

Storage directions:
Store at controlled
room temperature
15° to 30° C
(59° to 86° F)

**Pharmacist: Dispense
in this container with
patient leaflet attached.**

See package insert
for complete product
information.

Keep container
tightly closed.

Store at controlled
room temperature
15° to 30° C
(59° to 86° F).

U.S. Patent No. 3,987,052
815 831 001

The Upjohn Co.
Kalamazoo, MI
49001, USA

Drug manufacturer: Upjohn Co.

RL-1143 (03/05)

|||||


NDC number — NDC 0074-2453-11


Total volume — 1 mL

Dilaudid-HP[®] — Trade name

hydromorphone HCl — Generic name

10 mg — Dosage strength

Controlled substance schedule —  Rx only

 Mid. for: Abbott Laboratories — Drug manufacturer
N. Chicago, IL 60064, U.S.A.

Generic name — **CYTARABINE FOR INJECTION USP**

Directions for mixing — **FOR INTRAVENOUS, SUBCUTANEOUS, OR INTRATHECAL USE**

Route — **FOR INTRAVENOUS, SUBCUTANEOUS, OR INTRATHECAL USE**

Directions for storage — **500 mg**

Dosage strength — **500 mg**
50 mg per mL (after reconstitution) or 500 mg per 10 mL

Rx ONLY

Drug manufacturer — **Manufactured for: Bedford Laboratories™ Bedford, OH 44146**

NDC 55390-132-10 **LYOPHILIZED**


See package insert for complete prescribing information.

Each vial contains 500 mg and, if necessary, hydrochloric acid and/or sodium hydroxide for pH adjustment.

When reconstituted with 10 mL Bacteriostatic Water for Injection USP with benzyl alcohol, each mL contains 50 mg cytarabine. **Do not use a diluent containing benzyl alcohol for intrathecal and high dose investigational use.**

Store both powder and reconstituted solution at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Use reconstituted solution within 48 hours. Discard solution if a slight haze develops.

CYB-VB06



Trade name
Generic name

Each long-acting capsule contains 60 mg of propranolol hydrochloride.
Usual Dosage: See accompanying descriptive literature.
Manufactured for Akrimax Pharmaceuticals, LLC, Cranford, NJ 07016
By Wyeth Pharmaceuticals, Philadelphia, PA 19101
Marketed and Distributed by:
Akrimax Pharmaceuticals, LLC, Cranford, NJ 07016


PA4002857
8847M000
Rev. 01/08

NDC 24090-470-88 100 Capsules


Inderal® LA
(propranolol hydrochloride)
Long-Acting Capsules
60 mg

SEALED FOR YOUR PROTECTION


Rx only

 **AKRIMAX**
PHARMACEUTICALS


Store at 20° to 25° C (68° to 77° F); excursions permitted to 15° to 30° C (59° to 86° F). [See USP Controlled Room Temperature].
Protect from light, moisture, freezing, and excessive heat.
Dispense in a tight, light-resistant container as defined in the USP.



3 24090-470-88 9



Total amount in container (100 long-acting capsules)
Barcode
Form (long-acting capsules)



DURAGESIC® 100µg/h (FENTANYL TRANSDERMAL SYSTEM)

Route

NDC 50458-036-05 Five (100µg/h) Systems

DURAGESIC® 100µg/h (FENTANYL TRANSDERMAL SYSTEM)

Dosage strength (100 mcg per hour for 72 hours)

In vivo delivery of 100µg/h fentanyl for 72 hours

NOT FOR ACUTE OR POSTOPERATIVE USE

Each transdermal system contains:
10mg fentanyl and 0.4ml alcohol USP
DO NOT USE IF SEAL ON POUCH IS BROKEN
KEEP OUT OF REACH OF CHILDREN
Rx only

FOR USE IN OPIOID TOLERANT PATIENTS

Population medication used for

JANSSEN PHARMACEUTICA PRODUCTS, L.P.

CONTROL EXP. DATE

Exp.
Lot

NDC 0074-1973-14 100 Tablets

Usual adult dosage:

See package insert.

Total amount in container

Trade name

vicodin ES[®]

Storage: Store at 25°C (77°F);
excursions permitted to
15°-30°C (59°-86°F). [See USP
Controlled Room Temperature].

Form (extra strength)

Barcode



**hydrocodone bitartrate
and acetaminophen
tablets, USP**

Dispense in tight, light-resistant
container as defined in the USP.

Generic name

Do not accept if seal over bottle
opening is broken or missing.

Combined
medications

5 04-A245-R3
LQW11-R3 Rev 070708

Each tablet contains:
hydrocodone bitartrate 7.5 mg
acetaminophen 750 mg

©Abbott

Manufactured for
Abbott Laboratories
North Chicago, IL 60064 U.S.A.

Control medication
schedule

by Mallinckrodt Inc.
Hazelwood, MO 63042 U.S.A.

Rx only



NDC 0074-3956-46

NDC number

Kaletra[®]

Lopinavir/Ritonavir

Combined medications

Form of administration
(for oral use)

Oral Solution

80 mg/20 mg per mL

Total volume

160 mL

**ALERT: Find out about medicines
that should NOT be taken with
KALETRA**

Alert

**Attention Pharmacist: Do not cover
ALERT box with pharmacy label.**

Special instructions

**Dispense the enclosed Medication
Guide to each patient.**

04-A315-2/R4

Rx only



Abbott

Drug manufacturer



Can you list some important points to remember pertaining to medication labels?



1. Right Patient
2. Right Medication
3. Right Dosage
4. Right Route
5. Right Time
6. Right Documentation
7. Right Client Education
8. Right to Refuse
9. Right Assessment
10. Right Evaluation

Medication Administration

The End